Indivior Announces BARDA's First Order Of OPVEE Nasal Spray To Combat Opioids And Aid In National Preparedness; BARDA Will Use $8.7M In Project BioShield Designated Funding For The Initial Procurement

• BARDA purchased OPVEE, a nalmefene opioid overdose reversal nasal spray
• Through BARDA's contract with Indivior, communities will be better equipped to respond to mass poisoning emergencies and address biosecurity threats involving synthetic opioids

RICHMOND, Va., Aug. 26, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced the first order of OPVEE® (nalmefene) nasal spray from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to support its ongoing national preparedness efforts and help save lives during potential synthetic opioid overdose emergencies. OPVEE is the first and only nasal rescue medicine specifically indicated for synthetic opioids like fentanyl.